Generated by AI
Lantheus Holdings Inc. is a radiopharmaceutical-focused healthcare company that develops, manufactures, and commercializes diagnostic and therapeutic products used to help clinicians detect, localize, and monitor disease. Its portfolio centers on precision diagnostics and nuclear medicine solutions for oncology, cardiology, and neurology, with products designed to support imaging-based diagnosis and patient management across hospitals, clinics, and other healthcare settings. The company’s current business also includes radiotherapeutics and strategic partnerships that complement its core imaging franchise. Lantheus Holdings Inc. serves a global medical market where advanced diagnostic agents play an important role in guiding treatment decisions and improving disease visibility in clinical practice. Headquartered in Bedford, Massachusetts, Lantheus Holdings Inc. operates as a specialized provider in molecular imaging and related healthcare technologies.
Website201 Burlington Road
Bedford, MA, 01730
United States
The latest articles about LNTH.
Summary of Aug 3's posts. Generated by AI.
Summary of Aug 6's posts. Generated by AI.
Nine ETFs sold $22.8 million of Lantheus stock on Monday, against three buyers.
Summary of Aug 3's posts. Generated by AI.
Summary of Oct 3's posts. Generated by AI.
Investors talking about LNTH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.